Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

据公开信息，该候选药物拟治疗的适应症是被称为全球五大绝症之首的运动神经元疾病——渐冻症，渐冻症又名肌萎缩侧索硬化症（ALS），著名社会活动“冰桶挑战”源于渐冻症绝症患者的家庭和支持者。 此前，士泽生物另一款人异体通用“现货型”中脑多巴胺能神经前体细胞注射液（“XS-411注射液”）IND 申请获得国家药监局受理。据了解，该候选药物的适应症是 帕金森病 。

A new drug reimbursement principle is seen as a significant departure from value-based pricing. Despite concerns, the new pricing system could increase the availability of some orphan drugs by 35 per ...

The "Strategic Intelligence: Orphan Designated Drugs" report has been added to ResearchAndMarkets.com's offering.This report consolidates the latest thinking and forecasts around how the healthcare, ...

A patent has been granted in the US covering the use of Neurizon’s lead drug candidate NUZ-001 in neurodegenerative diseases ...

再鼎医药宣布，美国食品药品监督管理局（FDA）已授予ZL-1310孤儿药资格认定；ZL-1310是一款高活性的具有同类首创潜力的DLL3 ADC，用于治疗小细胞肺癌。 孤儿药（Orphan ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$ ...

Agreement drives continued patient access to four important therapies in Japan and KoreaStrengthens Essential Pharma and Clinigen’s combined ...